Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for FCN-437c. The small molecule drug candidate is under development for the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer in patients who have experienced disease progression after endocrine therapy combined with fulvestrant.
FCN-437c: A Selective CDK4/6 Inhibitor for Advanced Breast Cancer
FCN-437c is an oral, highly selective CDK4/6 inhibitor targeted at treating advanced/metastatic solid tumors, including HR+/HER2- advanced breast cancer. Globally, CDK4/6 inhibitors have become a cornerstone in the treatment of such cancers, with marketed inhibitors including Eli Lilly’s Verzenio (abemaciclib), Pfizer’s Ibrance (palbociclib), and Novartis’s Kisqali (ribociclib).- Flcube.com
